Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K23HL143053, U01 HL123033)
Vanderbilt Institute for Clinical and Translational Research (UL1TR002243, UL1 TR000445)
Received: 4 September 2020
Accepted: 7 January 2021
First Online: 5 February 2021
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board at Vanderbilt University (IRB #111510). Patients or their legally authorized representatives provided written informed consent before enrollment.
: Not applicable.
: W.H.S. reported personal fees from Baxter during the conduct of this study. T.W.R. reported personal fees from Cumberland Pharmaceuticals, Inc. and Avisa Pharma, LLC outside the submitted work. The remaining authors declare that they have no competing interests.